Logo image of NXO.CA

NEXOPTIC TECHNOLOGY CORP (NXO.CA) Stock Fundamental Analysis

Canada - TSX Venture Exchange - TSX-V:NXO - CA65341P1053 - Common Stock

0.01 CAD
0 (-33.33%)
Last: 7/15/2025, 7:00:00 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to NXO. NXO was compared to 15 industry peers in the Electronic Equipment, Instruments & Components industry. NXO may be in some trouble as it scores bad on both profitability and health. NXO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • NXO had negative earnings in the past year.
  • NXO had a negative operating cash flow in the past year.
  • In the past 5 years NXO always reported negative net income.
  • NXO had a negative operating cash flow in each of the past 5 years.
NXO.CA Yearly Net Income VS EBIT VS OCF VS FCFNXO.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

  • NXO has a worse Return On Assets (-505.57%) than 93.33% of its industry peers.
Industry RankSector Rank
ROA -505.57%
ROE N/A
ROIC N/A
ROA(3y)-921.95%
ROA(5y)-4359.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NXO.CA Yearly ROA, ROE, ROICNXO.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 5K -5K -10K -15K

1.3 Margins

  • NXO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NXO.CA Yearly Profit, Operating, Gross MarginsNXO.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

0

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, NXO has more shares outstanding
  • The debt/assets ratio for NXO is higher compared to a year ago.
NXO.CA Yearly Shares OutstandingNXO.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
NXO.CA Yearly Total Debt VS Total AssetsNXO.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -1602.31, we must say that NXO is in the distress zone and has some risk of bankruptcy.
  • NXO has a worse Altman-Z score (-1602.31) than 93.33% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1602.31
ROIC/WACCN/A
WACCN/A
NXO.CA Yearly LT Debt VS Equity VS FCFNXO.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M 60M

2.3 Liquidity

  • NXO has a Current Ratio of 0.04. This is a bad value and indicates that NXO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • NXO's Current ratio of 0.04 is on the low side compared to the rest of the industry. NXO is outperformed by 93.33% of its industry peers.
  • NXO has a Quick Ratio of 0.04. This is a bad value and indicates that NXO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • NXO has a worse Quick ratio (0.04) than 93.33% of its industry peers.
Industry RankSector Rank
Current Ratio 0.04
Quick Ratio 0.04
NXO.CA Yearly Current Assets VS Current LiabilitesNXO.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 88.30% over the past year.
EPS 1Y (TTM)88.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
NXO.CA Price Earnings VS Forward Price EarningsNXO.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NXO.CA Per share dataNXO.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0 -0 -0.01 -0.01 -0.01

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • NXO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEXOPTIC TECHNOLOGY CORP

TSX-V:NXO (7/15/2025, 7:00:00 PM)

0.01

0 (-33.33%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)07-23
Earnings (Next)08-27
Inst Owners0.01%
Inst Owner ChangeN/A
Ins Owners8.61%
Ins Owner ChangeN/A
Market Cap1.95M
Revenue(TTM)N/A
Net Income(TTM)-390.30K
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -505.57%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-921.95%
ROA(5y)-4359.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.04
Quick Ratio 0.04
Altman-Z -1602.31
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.33%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y79.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y97.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y97.77%
OCF growth 3YN/A
OCF growth 5YN/A

NEXOPTIC TECHNOLOGY CORP / NXO.CA FAQ

What is the ChartMill fundamental rating of NEXOPTIC TECHNOLOGY CORP (NXO.CA) stock?

ChartMill assigns a fundamental rating of 0 / 10 to NXO.CA.


What is the valuation status for NXO stock?

ChartMill assigns a valuation rating of 0 / 10 to NEXOPTIC TECHNOLOGY CORP (NXO.CA). This can be considered as Overvalued.


How profitable is NEXOPTIC TECHNOLOGY CORP (NXO.CA) stock?

NEXOPTIC TECHNOLOGY CORP (NXO.CA) has a profitability rating of 0 / 10.


How financially healthy is NEXOPTIC TECHNOLOGY CORP?

The financial health rating of NEXOPTIC TECHNOLOGY CORP (NXO.CA) is 0 / 10.